Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ: SAVA )

2.770 +0.160 (+6.13%)
Streaming Delayed Price Updated: 11:58 AM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Crude Oil Rises 2%; Five Below Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates
Via Benzinga
ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
From Cassava Sciences, Inc.
Via GlobeNewswire
Peering Into Cassava Sciences's Recent Short Interest
Via Benzinga
3 Healthcare Stocks to Sell in July Before They Crash & Burn
Many healthcare names are attractive. But drugstore chains and some drug makers have poor outlooks. Here are three healthcare stocks to sell. 
Via InvestorPlace
Top 5 Health Care Stocks That May Explode In July
Via Benzinga
3 Biotech Stocks to Sell in July Before They Crash & Burn
While biotech stocks have potential to provide high returns, they are often overly dependent on drug approvals. Sell these before its too late 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Cassava Sciences Stock Is Sinking Today
The biotech stock is feeling the heat from an indictment of a former consultant. 
Via The Motley Fool
Planet Labs Layoffs 2024: What to Know About the Latest Planet Job Cuts
Planet Labs layoffs are a hot topic on Monday as the satellite company prepares to cut 180 jobs, or 17% of its workforce, to reduce costs. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
Cassava Sciences is cooperating with DOJ and SEC investigations involving its Alzheimer's drug simufilam. An internal committee is examining new SEC information, while the company advances its Phase 3... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Are Stocks Down Today?
Stocks are down today and investors wondering why have come to the right place as we know what's sending shares lower on Monday! 
Via InvestorPlace
SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud
SAVA stock is trading lower after a scientist behind Cassava's simufilam was charged with manipulating research data to justify his grants. 
Via InvestorPlace
Cassava Shares Are Down Over 30%: Here's Why
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading significantly lower on Friday following the indictment of Hoau-Yan Wang, a tenured medical professor and advisor to the company, by a federal... 
Via Benzinga
Cassava Sciences Issues Statement on Former Science Advisor
From Cassava Sciences, Inc.
Via GlobeNewswire
Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich
These three biotech stocks to buy carry risks but may appeal to speculative investors with time and patience. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024
SAVA stock results show that Cassava Sciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share 
From Cassava Sciences, Inc.
Via GlobeNewswire
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
From Cassava Sciences, Inc.
Via GlobeNewswire
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Biotech Stocks
As the stock market corrects, focusing on stable investments is crucial. This is why you should steer clear of these biotech stocks to avoid. 
Via InvestorPlace
Redemption Date Announced for Warrants
From Cassava Sciences, Inc.
Via GlobeNewswire
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings. 
Via Benzinga
CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
From Schall Law
Via GlobeNewswire
SAVA FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA
WHY: NEW YORK, NY - (NewMediaWire) - April 01, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between August 18,... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
SAVA FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.